Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down to $16.98

Tyra Biosciences, Inc. (NASDAQ:TYRA) shares gapped down prior to trading on Thursday . The stock had previously closed at $16.98, but opened at $15.80. Tyra Biosciences shares last traded at $15.80, with a volume of 1,351 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on TYRA shares. HC Wainwright restated a “buy” rating and issued a $23.00 target price on shares of Tyra Biosciences in a research note on Wednesday, June 5th. Oppenheimer restated an “outperform” rating and issued a $28.00 target price (up from $25.00) on shares of Tyra Biosciences in a research note on Monday, May 13th. Finally, Wedbush restated an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research note on Friday, May 10th.

Tyra Biosciences Stock Performance

The business has a 50 day moving average of $17.57 and a 200-day moving average of $16.50.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.11. On average, research analysts anticipate that Tyra Biosciences, Inc. will post -1.71 earnings per share for the current year.

Insider Activity at Tyra Biosciences

In related news, COO Daniel Bensen sold 3,502 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $20.00, for a total transaction of $70,040.00. Following the sale, the chief operating officer now directly owns 427,981 shares in the company, valued at approximately $8,559,620. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 15.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Tyra Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Kynam Capital Management LP bought a new position in Tyra Biosciences in the 4th quarter worth about $4,712,000. AJOVista LLC bought a new position in Tyra Biosciences in the 4th quarter worth about $59,000. Wellington Management Group LLP increased its stake in Tyra Biosciences by 18.5% in the 3rd quarter. Wellington Management Group LLP now owns 94,112 shares of the company’s stock worth $1,296,000 after acquiring an additional 14,676 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in Tyra Biosciences by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 9,531 shares of the company’s stock worth $132,000 after acquiring an additional 2,417 shares during the last quarter. Finally, Federated Hermes Inc. increased its stake in Tyra Biosciences by 1,244.2% in the 4th quarter. Federated Hermes Inc. now owns 2,070 shares of the company’s stock worth $29,000 after acquiring an additional 1,916 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.